<DOC>
	<DOCNO>NCT02907996</DOCNO>
	<brief_summary>The objective study collect ass data relate safety effectiveness Sovaldi treatment regimen , per approve prescribe information Sovaldi , routine clinical practice report result Korean Ministry Food Drug Safety ( MFDS ) .</brief_summary>
	<brief_title>Evaluate Safety Effectiveness Sovaldi Treatment Regimens Patients With Chronic Hepatitis C Virus ( HCV ) Infection Korean Real-World Setting</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Patients age 18 year old live Korea Patients chronic HCV infection eligible treatment Sovaldi indicate approve prescribe information Sovaldi . Patients informed pertinent aspect study voluntarily sign informed consent form Key Patients treat Sovaldi outside approve prescribe information Sovaldi Korea Patients contraindication ( refer Korea prescribe information ) Patients contraindication ribavirin peginterferon alfa Daklinza Pregnant breast feeding woman Patients previously administer Sovaldi Patients participate concurrent HCV clinical trial Patients plan leave country study period Note : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>